Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119084 | 0.92 | PIK3CD (0.40) | PIK3CDGAAKDM4EGLACYP2D6 | |
| SCHEMBL22013047 | 0.91 | PIK3CD (0.52) | PIK3CDGAAKDM4ECYP2D6SMN1; SMN2 | |
| SCHEMBL14328666 | 0.91 | PIK3CD (0.52) | PIK3CDGAAKDM4ECYP2D6SMN1; SMN2 | |
| SCHEMBL101927 | 0.91 | PIK3CD (0.52) | PIK3CDGAAKDM4EGLACYP2D6 | |
| SCHEMBL7907337 | 0.91 | PIK3CD (0.52) | PIK3CDGAAKDM4ECYP2D6SMN1; SMN2 | |
| SCHEMBL22300882 | 0.91 | PIK3CD (0.52) | PIK3CDGAAKDM4ECYP2D6SMN1; SMN2 | |
| SCHEMBL14328670 | 0.84 | PIK3CD (0.46) | PIK3CDGAAKDM4EPOLBTSHR | |
| SCHEMBL14328851 | 0.84 | PIK3CD (0.46) | PIK3CDGAAKDM4EPOLBTSHR | |
| SCHEMBL13907143 | 0.84 | PIK3CD (0.47) | PIK3CDKDM4ECYP2D6SMN1; SMN2MAPT | |
| SCHEMBL2323195 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010629-B2 | Compositions and methods for in vivo imaging | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-03 | — | — | US | disclosed |
| US-20150343094-A1 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150343094-A1 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | PLIN3, SGMS1, SGMS2 | PIK3CD 420/4885GAA 955/4885KDM4E 3957/4885 |
| US-10010629-B2 | Compositions and methods for in vivo imaging | PLIN3, SGMS1, SGMS2 | PIK3CD 420/4885GAA 955/4885KDM4E 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.